Display Settings:

Items per page
We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

Results: 8

1.
Figure 7

Figure 7. From: FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting.

Negative correlation of serum FGF-23 levels with serum phosphate (a and b) and TmP/GFR (c and d) in pediatric and adult FD patients.

Mara Riminucci, et al. J Clin Invest. 2003 September 1;112(5):683-692.
2.
Figure 4

Figure 4. From: FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting.

Expression of FGF-23 in FD tissue from patients with normal phosphatemia and TmP/GFR. (ac) Images are from one patient. (df) Images from a second patient. (c and f) Sections hybridized with the sense (control) probe. Signal for FGF-23 mRNA is observed in both cases (a and b, d and e).

Mara Riminucci, et al. J Clin Invest. 2003 September 1;112(5):683-692.
3.
Figure 8

Figure 8. From: FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting.

Positive correlation of serum FGF-23 with disease burden assessed as percentage of skeletal involvement in bone scintigrams (a and b) and with markers often used to assess FD activity, ALP (c and d) and deoxypyridinoline (e and f), for pediatric and adult FD patients. CR, creatinine.

Mara Riminucci, et al. J Clin Invest. 2003 September 1;112(5):683-692.
4.
Figure 3

Figure 3. From: FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting.

Immunohistochemical characterization of FGF-23–producing cells in FD. Stromal cells in the fibrous tissue (ft) express FGF-23 mRNA (a), are intensely positive for the early markers of osteogenic differentiation, ALP (b) and ON (c), but are negative for the markers of late osteogenic differentiation, BSP (d) and OC (not shown). Both ALP and ON immunostaining result in decoration of a dense network of delicate cell processes of FD stromal cells. Mature osteogenic cells embedded as osteocytes in newly formed FD bone express the late marker of osteogenic differentiation, and OC (not shown) (e), and express FGF-23 mRNA (f).

Mara Riminucci, et al. J Clin Invest. 2003 September 1;112(5):683-692.
5.
Figure 2

Figure 2. From: FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting.

Immunohistochemical characterization of FGF-23–producing cells in FD. Undecalcified MMA sections (a and b) and paraffin sections (cf) were prepared from the same tissue sample. (a and b) Von Kossa staining of MMA sections demonstrates the severe mineralization defect in FD bone, reflected in a significant excess of osteoid (ost) and paucity of mineralized bone matrix (mb; black with von Kossa). (c and d) Immunolocalization of ALP. Cells layered onto trabecular bone surfaces (double arrows in c and d) are intensely ALP positive. (e and f) FGF-23 in situ hybridization. The codistribution of the hybridization signal with the immunoreactivity for ALP (double arrows in c and e, respectively) is shown. Also note that osteocytes within FD bone do express FGF-23 (f), but are ALP negative (d).

Mara Riminucci, et al. J Clin Invest. 2003 September 1;112(5):683-692.
6.
Figure 5

Figure 5. From: FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting.

In situ hybridization analysis of FGF-23 expression in normal bone. (ad) Normal trabecular bone (iliac crest). (a and c) Antisense probe; (b and d) sense (control) probe. Hybridization signal is observed over flattened bone-lining cells (surface-associated quiescent osteogenic cells [a, arrows] and osteocytes [a and c, arrowheads]). (ei) Normal fracture callus. bv, blood vessel lumen. (e, g, i) Antisense probe. (f and h) Sense (control) probe. Intense hybridization signal is observed in osteoblasts (e and g, arrows) actively involved in deposition of reparative bone (b) and in newly formed osteocytes therein (g, arrowheads). (i) Periosteum and subperiosteal bone. Note the expression of FGF-23 in periosteal osteoprogenitor cells (p).

Mara Riminucci, et al. J Clin Invest. 2003 September 1;112(5):683-692.
7.
Figure 1

Figure 1. From: FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting.

In situ hybridization analysis of FGF-23 expression in FD of bone. Biopsy specimens of FD-involved iliac crest. Serial sections from two FD phosphaturic patients were hybridized with antisense and sense RNA probes for FGF-23 mRNA. (af) Patient 1. (a and b) Expression of FGF-23 is clearly observed both in the fibrous component of the lesion and in bone cells associated with abnormal bone trabeculae (a). No signal is observed in sections hybridized with the sense (control) probe (b). (c and d) Strong expression of FGF-23 mRNA is observed in the abnormal bone cells associated with the surface of abnormal bone trabeculae (double arrows) and with individual osteocytes therein (arrowheads) (d). (e and f) Expression of FGF-23 mRNA is also observed in cells (endothelial cells and/or pericytes) within the walls of microvessels in the FD tissue (single arrows). (gi) Patient 2. Strong hybridization signal in abnormal bone cells (g, i, j; thick arrows in j) and in spindle-shaped fibroblastic cells in the fibrous tissue (thin arrows in j). No signal is detected in sections hybridized with the sense probe (h). ft, fibrous tissue; b, bone; bv, blood vessel lumen.

Mara Riminucci, et al. J Clin Invest. 2003 September 1;112(5):683-692.
8.
Figure 6

Figure 6. From: FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting.

Expression of FGF-23 mRNA and protein. (a) RT-PCR primer sets that generate 251- and 373-bp products. FGF-23 mRNA was identified in fresh FD tissue (lane 1), in normal, nonclonal bone marrow stromal cells (BMSC) and multicolony-derived strains (MCDS) from a normal donor (lane 2), nonclonal strains of FD-derived stromal cells (comprising mutated and nonmutated cells) (lane 3), in pure strains of GNAS1-mutated stromal cells (FD 100% mut) (lane 4), and in HTB cells from normal (lanes 5 and 6) and FD (lane 7) donors. The identity of the amplification product was verified by DNA sequencing. (b) Conditioned medium from serum-free cultures of normal bone marrow stromal cells (BMSC), FD-derived nonclonal multicolony (mixed) strains and pure strains of GNAS1-mutated stromal cells (FD 100% mut), and normal and FD HTB cells (HTB) were harvested at 24 hours and analyzed by ELISA for production of FGF-23. Measurable levels of FGF-23 were observed in all cultures, with no significant difference between GNAS1-mutation status or type of cell culture. The values represent the combined results of two separate experiments and error bars represent standard error of the mean. Standard medium (containing 15% FBS) does not contain detectable FGF-23. RIU, relative immunoreactive unit.

Mara Riminucci, et al. J Clin Invest. 2003 September 1;112(5):683-692.

Display Settings:

Items per page

Supplemental Content

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Write to the Help Desk